We demonstrated that targeting USP14 and UCHL5 by b‐AP15 showed obvious antitumour efficiency in BCR‐ABLWT and BCR‐ABLT315I CML cell lines and xenografts, as well as in primary CML cells. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.